LSE · AVCT.L
Avacta Group Plc
£0.61-£0.01 (-0.82%)
Avacta Group Plc’s quoted price sits in the lower half of its reported 52-week range, 34.24% below the high.
Loading market information…
LSE · FARN.L · GBp
Stock price, earnings
Quote as of Oct 30, 2026, 11:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Faron Pharmaceuticals Oy’s quoted price sits in the lower half of its reported 52-week range, 85.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Faron Pharmaceuticals Oy’s next earnings report is currently expected on Mar 19, 2027, with estimated earnings per share of -£0.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Faron Pharmaceuticals Oy’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in Turku, Finland, in 2003, Faron Pharmaceuticals Oy operates as a clinical-stage biotechnology firm dedicated to the discovery and advancement of novel pharmaceutical solutions. The company's core focus lies in harnessing immune modulation to develop proprietary drug candidates addressing significant unmet medical needs. Their pipeline spans critical areas such as immuno-oncology, organ safeguarding, and regenerative medicine. Among its leading therapeutic candidates is Traumakine, an intravenous interferon beta-1a treatment under investigation for conditions including acute respiratory distress syndrome (ARDS), COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury. Another key asset is Bexmarilimab, an innovative precision cancer immunotherapy designed to target solid tumors, non-small cell lung carcinoma, and hematological malignancies. Additionally, Faron is developing Haematokine, a new chemical entity acting as an AOC3 inhibitor, aimed at treating hematological malignancies and bone marrow-related conditions.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:50 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| £8.67M-29.35% vs estimate |
| Q2 2023 | Aug 23, 2023 | -£0.15+26.67% vs estimate | £0.00-100.0% vs estimate |
|---|
| Q4 2022 | Mar 2, 2023 | -£0.19-54.28% vs estimate | £0.00-100.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.61-£0.01 (-0.82%)
Avacta Group Plc’s quoted price sits in the lower half of its reported 52-week range, 34.24% below the high.
£1.17-£0.00 (-0.17%)
PureTech Health plc’s quoted price sits in the lower half of its reported 52-week range, 18.25% below the high.
£0.54£0.00 (0.0%)
Beximco Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 16.92% below the high.
£0.87-£0.02 (-1.8%)
Scancell Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 70.37% below the high.
£20.00-£0.25 (-1.23%)
Bioventix PLC’s quoted price sits in the upper half of its reported 52-week range, 11.31% below the high.
£5.30£0.00 (0.0%)
4basebio PLC’s quoted price sits in the lower half of its reported 52-week range, 35.37% below the high.
£0.10£0.00 (0.0%)
Ondine Biomedical Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.1% below the high.
£5.66-£1.14 (-16.76%)
Hemogenyx Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 53.61% below the high.
